Alk-Abello AS

4AJ0

Company Profile

  • Business description

    Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.

  • Contact

    Boge Alle 6-8
    HorsholmDK-2970
    DNK

    T: +45 45747576

    E: [email protected]

    https://www.alk.net

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    2,711

Stocks News & Analysis

stocks

Lowering profit forecasts on Aussie airlines

The impact of the oil price surge.
stocks

AI isn’t an economic moat killer, but it will disrupt industries

How we’re rethinking companies’ competitive advantages in an AI-first world.
stocks

AI lands a blow on some Aussie stocks – yet stands to benefit others

AI is reshaping ASX tech moats - but some are more insulated than others.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,745.3066.700.77%
CAC 407,743.9217.720.23%
DAX 4022,636.9116.95-0.07%
Dow JONES (US)46,124.0684.41-0.18%
FTSE 1009,965.1671.010.72%
HKSE25,261.35197.640.79%
NASDAQ21,761.89184.87-0.84%
Nikkei 22553,749.621,497.342.87%
NZX 50 Index12,929.30227.551.79%
S&P 5006,556.3724.63-0.37%
S&P/ASX 2008,534.3045.700.54%
SSE Composite Index3,931.8450.561.30%

Market Movers